GHENT, BELGIUM--(Marketwire - July 27, 2010) -
GHENT, Belgium, 27 July 2010 - Ablynx [Euronext Brussels: ABLX] today
announced
that its Chief Scientific Officer, Debbie Law, has resigned from her
position at
Ablynx, effective 31 August, as she will be returning to the USA with her
family
for personal reasons.
The Ablynx senior management will work closely to ensure continuity of scientific strategy and progress until a replacement for Dr. Law has been identified. "It has been a pleasure working with Debbie who brought great knowledge, biologics experience and passion to Ablynx. We thank Debbie for her accomplishments and commitment to Ablynx and greatly appreciate all she has done to help us develop Ablynx into what we believe is one of the most advanced independent, next generation biologics companies. We wish her the best of luck in returning to the USA," said Dr. Edwin Moses, Chairman and Chief Executive Officer.
[HUG#1434246]
Complete version of the press release: http://hugin.info/137912/R/1434246/379923.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Ablynx via Thomson Reuters ONE
For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /+32 (0)473 39 50 68
e: Email Contact
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 /
+44 (0)7990 570 900
e: Email Contact
